SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# PRODUCT INFORMATION

## PCI 34051

*Item No. 10444*

| | |
|---|---|
| **CAS Registry No.:** | 950762-95-5 |
| **Formal Name:** | N-hydroxy-1-[(4-methoxyphenyl)methyl]-1H-indole-6-carboxamide |
| **MF:** | $C_{17}H_{16}N_2O_3$ |
| **FW:** | 296.3 |
| **Purity:** | ≥95% |
| **UV/Vis.:** | $\lambda_{max}$: 230, 285 nm |
| **Supplied as:** | A crystalline solid |
| **Storage:** | -20°C |
| **Stability:** | ≥2 years |




*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

### Laboratory Procedures

PCI 34051 is supplied as a crystalline solid. A stock solution may be made by dissolving the PCI 34051 in the solvent of choice. PCI 34051 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of PCI 34051 in these solvents is approximately 0.3, 50, and 5 mg/ml, respectively.

PCI 34051 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PCI 34051 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PCI 34051 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

PCI 34051 is a potent histone deacetylase (HDAC) 8 inhibitor ($IC_{50}$ = 0.01 µM) with >200-fold selectivity over HDAC isoforms 1, 2, 3, 6, and 10 ($IC_{50}$s = 4, >50, >50, 2.9, and 13 µM, respectively).[1] PCI 34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias ($GI_{50}$s = 2.4 - 4 µM), but not in other hematopoietic or solid tumor lines.[1] This compound has also been used to support a critical role for HDAC8 in the coordinated deacetylation of the core cohesion component SMC3 during mitosis.[2]

### References


1. Balasubramanian, S., Ramos, J., Luo, W., *et al.* A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. *Leukemia* **22(5)**, 1026-1034 (2008).
2. Deardorff, M.A., Bando, M., Nakato, R., *et al.* HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature* **489(7415)**, 313-317 (2012).





**CAYMAN CHEMICAL**
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
**PHONE:** [800] 364-9897
[734] 971-3335
**FAX:** [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM